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Systematic review and mixed treatment
comparison of intravitreal aflibercept with
other therapies for diabetic macular
edema (DME)
Jean-Francois Korobelnik1, Jos Kleijnen2, Shona H Lang3, Richard Birnie3, Regina M Leadley3, Kate Misso3,
Gill Worthy3, Dominic Muston4* and Diana V Do5
Abstract
Background: This was an indirect comparison of the effectiveness of intravitreal aflibercept (IVT-AFL) 2 mg every
8 weeks after 5 initial monthly doses (or if different periods, after an initial monthly dosing period) (2q8) and other
diabetic macular edema (DME) therapies at doses licensed outside the USA.
Methods: A comprehensive search was undertaken to source relevant studies. Feasibility networks were prepared
to identify viable comparisons of 12-month outcomes between IVT-AFL 2q8 and therapies licensed outside the
USA, which were assessed for clinical and statistical homogeneity. Pooled effect sizes (mean difference [MD] and
relative risk/risk ratio [RR]) were calculated using fixed- and random-effects models. Indirect comparisons were
performed using Bucher analysis. If at least one ‘head-to-head’ study was found then a mixed treatment comparison
(MTC) was performed using Bayesian methods. Two 12-month comparisons could be undertaken based on indirect
analyses: IVT-AFL 2q8 versus intravitreal ranibizumab (IVR) 0.5 mg as needed (PRN) (10 studies) and IVT-AFL 2q8 versus
dexamethasone 0.7 mg implants (three studies).
Results: There was an increase in mean best-corrected visual acuity (BCVA) with IVT-AFL 2q8 over IVR 0.5 mg PRN
by 4.67 letters [95% credible interval (CrI): 2.45–6.87] in the fixed-effect MTC model (10 studies) and by 4.82 letters
[95% confidence interval (CI): 2.52–7.11] in the Bucher indirect analysis (four studies). IVT-AFL 2q8 doubled the
proportion of patients gaining≥ 10 Early Treatment Diabetic Retinopathy Study letters at 12 months compared with
dexamethasone 0.7 mg implants (RR = 2.10 [95% CI: 1.29–3.40]) in the fixed-effect model. There were no significant dif-
ferences in safety outcomes between IVT-AFL 2q8 and IVR 0.5 mg PRN or dexamethasone 0.7 mg implants.
Conclusions: Studies of IVT-AFL 2q8 showed improved 12-month visual acuity measures compared with studies of
IVR 0.5 mg PRN and dexamethasone 0.7 mg implants based on indirect comparisons. These analyses are subject to
a number of limitations which are inherent in indirect data comparisons.
Keywords: Intravitreal aflibercept, Diabetic macular edema (DME), Intravitreal ranibizumab, Meta-analysis,
Systematic review
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Background
Severe retinopathy and presence of diabetic macular
edema (DME) are associated with vision loss in patients
with diabetes [1]. Although focal laser photocoagulation
has been the standard of care for DME [2] it can only
slow progression and its ability to reverse vision loss is
low [3]. Awareness of the role of vascular endothelial
growth factors (VEGF and placental growth factor [PIGF])
and inflammatory mediators in stimulating retinal vascu-
logenesis and angiogenesis [4] has led to the development
and widespread use of anti-VEGF agents that can target
these pathways [5,6].
Intravitreal aflibercept (IVT-AFL), which is composed of
extracellular domains from human VEGF receptors 1 and
2 fused to the Fc portion of human immunoglobulin-G1
(IgG1), is a VEGF-A and PIGF inhibitor that blocks retinal
cell migration and proliferation. Preclinical studies have
shown that it has a longer duration of action than other
anti-VEGF agents, and has 100-fold greater binding
affinity to VEGF-A than intravitreal ranibizumab (IVR)
(a recombinant humanized monoclonal antibody that
inhibits VEGF-A) [7-10]. Clinical studies have demon-
strated the efficacy and safety of these anti-VEGF agents
compared with laser in DME patients [11-16]. The IVT-
AFL studies have supported its European license (i.e.,
five 2 mg injections every 4 weeks followed by 2 mg
injections every 8 weeks [2q8]; with no requirement for
monitoring between injections; after the first 12 months
of treatment with IVT-AFL, the treatment interval may
be extended based on visual and anatomic outcomes;
the schedule for monitoring should be determined by
the treating physician).
Meta-analyses have been undertaken to compare anti-
VEGF agents, based on a lack of direct comparisons
prior to the recent publication of the Protocol T study
[17-20]. However, some analyses have pooled IVR studies
regardless of the posology or the nature of the comparator,
and comparisons involving IVT-AFL have been based on
only the DAVINCI study, which differs in design from the
more recent phase III VIVID-DME and VISTA-DME
studies in many aspects, including loading phase (DA
VINCI included three initial loading doses in some arms
compared with five in VIVID-DME and VISTA-DME)
[11,13]. In addition, the meta-analysis by Virgili et al. [18]
contained a limited and exploratory indirect comparison
of differences in efficacy among anti-VEGF agents (3-line
gains only).
The aims of this study were to systematically identify
and review studies informing the clinical effectiveness of
IVT-AFL 2q8 in relation to comparator treatments and
0.7 mg or fluocinolone acetate 0.2 μg/day. Unlike the
meta-analysis by Virgili et al. [18], this study will consider
a broader range of outcomes (including reporting of
best-corrected visual acuity [BCVA] based on letters,
which is used in most studies, rather than logarithm of
the minimal angle of resolution) and will focus on a
comparison of licensed anti-VEGF agents. The need for
such an approach was supported by the limited out-
come of the Virgili et al. meta-analysis [18].
Methods
Search strategy
A comprehensive search was undertaken to identify rele-
vant studies. To reduce the risk of bias and error, the
database selection, systematic literature search and re-
view adhered to guidelines for the Institut fur Qualitat
und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
methods guide (Version 4.0), the Cochrane Collabor-
ation and Centre for Review and Dissemination (York,
UK) [21-23].
Search strategies were developed specifically for each
database and used a variety of synonyms for DME. The
following databases were searched from inception:
Medline (1946–2013/10); Medline In-Process Citations
and Daily Update (up to 2013/10/13); Embase (1974–
2013/10); Cochrane Central Register of Controlled Trials
(up to 2013/10/15). The main search strategy for Embase
is listed in Additional file 1: Appendix 1. A number of
other searches were also undertaken, including other data-
bases (rapid appraisal), websites, and congress abstracts,
which are listed in Additional file 1: Appendix 2. The
bibliographies of identified research and review articles
were also checked for studies. In addition, the final in-
cluded papers were checked on PubMed for retractions
and errata. Additional data (including abstracts for any
unpublished studies at the time of literature review) were
provided by Bayer HealthCare (Berlin, Germany).
Inclusion criteria
Studies were included if they met the PICOS criteria
(populations, interventions, comparators, outcomes and
study design) and prespecified requirements for inclu-
sion in indirect and mixed treatment analyses (Table 1).
The additional criteria for study selection exclude studies
that cannot inform mixed treatment comparisons of IVT-
AFL 2q8 versus comparators of interest (IVR 0.5 mg PRN,
and implants of dexamethasone 0.7 mg or fluocinolone
acetonide 0.2 μg/day) for outcomes at 12 months. The
population criterion (‘patients with DME’) was deliberately
inclusive, irrespective at this stage of features such as
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Table 1 An overview of the PICOS and other criteria used for study inclusion and exclusion
Criteria Inclusion Exclusion
Study design Published and unpublished randomized
controlled studies
Systematic or non-systematic reviews and
meta-analyses
Dose or frequency comparison studies Preclinical studies, retrospective prognostic
studies, and case reports
Ad-hoc analyses of randomized controlled
study data Editorials, commentaries, letters, and consensus
reports
Crossover randomized controlled studies
Pilot studies (if phase not mentioned), phase
I and II randomized controlled studies (to be
included as second-level evidence, if primary
evidence is unavailable)
Controlled observational studies (to be included
as second-level evidence, if primary evidence is
unavailable)
Separate searches will be performed as
required
Single dose of intervention studies
Studies of less than 3 months follow-up
Population Patients with DME
Interventions Eylea/VEGF Trap-Eye/aflibercept Systemic treatments (alone or in combination
with intervention)
Anti-VEGF treatments (any including
ranibizumab/Lucentis, bevacizumab/Avastin,
and pegaptanib/Macugen)
Surgery (alone or in combination with
intervention)
Subtenon injectionsIntravitreal steroids (any including triamcinolone,
fluocinolone acetonide/Iluvien, dexamethasone/
Ozurdex, and implants)
Laser treatments
NOTE the intervention should be to treat the
DME not to treat cataracts
The above interventions can be included if
combined with other treatments (e.g., eye drops)
except the exclusions
Comparators Placebo, best standard care, masked control,
sham, and eye drops
Systemic treatments (alone or in combination
with intervention)
Any intervention (from those listed as interventions) Surgery (alone or in combination with
intervention)
NOTE: this can be a single treatment/implant
Clinical Outcomes Number of injections/visits/assessments
BCVA (mean change from baseline, mean
average change from baseline, as measured by
ETDRS score or Snellen equivalent)
Loss of ≤ 15, ≥ 15, ≥ 30 ETDRS letters
Gain of≥ 0, 10, 15, 30 ETDRS letters
20/40 vision or better (Snellen chart)
20/200 or worse (Snellen chart)
Reduction in laser use
Anatomical changes (e.g., change in CNV and
lesion area, central foveal thickness, and
fluid on OCT)
Health-related quality of life (EQ-5D, NEI VFQ-25,
and other scales)
Korobelnik et al. BMC Ophthalmology  (2015) 15:52 Page 3 of 15
Institutional Review Boards/independent ethics commit-
tees, and enrolled patients that provided informed consent
to participate in them.
Data extraction and quality assessment
Titles and abstracts identified through the search strat-
egies described were independently screened by two
reviewers, and any references which did not meet the
inclusion criteria listed previously were excluded.
During the screening of conference abstracts, only
studies which specifically mentioned randomization
and which reported extractable outcome data (or base-
line or subgroup data) were included. Full paper copies
were obtained for the remaining references, which were
examined in detail to determine whether they met the
inclusion criteria. All papers excluded at this second
stage of the screening process were documented along
with the reasons for exclusion. Any discrepancies
between reviewers were resolved through discussion or
the intervention of a third reviewer. A similar approach
was undertaken for data extraction and quality assessment.
Data extraction forms were designed and piloted by
reviewers. To avoid duplication of data where studies
(or study populations) had multiple publications, the
most recent and complete report was used as the main
Risk of Bias Tool for randomized controlled trials [22].
In brief, bias was graded as low risk, high risk or unclear
in several domains (selection, performance, detection,
attrition, reporting, and other).
Statistical analyses
The analysis approach was predefined in the study protocol.
Based on the descriptive summary of all of the included
studies, a feasibility assessment was undertaken to deter-
mine which comparisons and outcomes could be included.
Studies could not be included in indirect analyses if: they
were connected by one arm only and did not form a closed
network, unless they included comparators of interest;
formed loops but did not lie along the path between IVT-
AFL 2q8 and comparators of interest (IVR 0.5 mg PRN,
and implants of dexamethasone 0.7 mg or fluocinolone
acetonide 0.2 μg/day); or did not report 12-month out-
comes. For any direct ‘head-to-head’ comparisons between
two treatments, studies were pooled using meta-analysis,
following methods recommended by the Cochrane
Handbook [22]. Forest plots of effect sizes were prepared for
each of the outcomes. Dichotomous outcomes were re-
ported as relative risks/risk ratios (RR) and odds ratios (OR)
with 95% confidence intervals (CI) and continuous outcomes
were reported as mean differences (MD) with 95% CI.
Table 1 An overview of the PICOS and other criteria used for study inclusion and exclusion (Continued)
diabetic macular/retinal edema, reduced visual
acuity, vitreous hemorrhage, corneal abrasion,
and any others)
AE (all AE, all ocular AE, all non-ocular AE, retinal
detachment, retinal ischemia, lens damage, all
grades of ocular inflammation, eye pain, increased
ocular pressure, retinal degradation, macular edema,
cataract, neovascularization, and any others)
Serious non-ocular AE (all, non-fatal cardiac infarction,
non-fatal stroke, non-ocular hemorrhage, hypertension,
serious systemic events, arterial thrombotic events, and
venous thrombotic events)
Language Any
Additional criteria necessary for inclusion
in indirect and mixed treatment analysis
Studies that were connected by one arm
only and did not form a closed network,
unless they included comparators of interest
Studies that formed loops but did not lie
along the path between IVT-AFL 2q8 versus
comparators of interest (IVR 0.5 mg PRN, or
implants of dexamethasone 0.7 mg or
fluocinolone acetonide 0.2 µg/day)
Studies that did not report 12-month
outcomes
AE, adverse event; BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; DME, diabetic macular edema; EQ-5D, EuroQoL-5D; ETDRS, Early Treatment
Diabetic Retinopathy Study; IVR, intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; NEI VFQ-25, National Eye Institute 25-item Visual Function questionnaire; OCT,
optical coherence tomography; PRN, as-needed; VEGF, vascular endothelial growth factor.
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considered to be sufficiently similar and suitable for
meta-analysis if I2 < 75% based on the following
categorization of heterogeneity: low (0–25%), moderate
(26–75%) and high (> 75%) [24]. The judgment of clin-
ical homogeneity was based on study design, risk of
bias, inclusion/exclusion criteria, baseline participant
characteristics and treatment regimen.
Data were pooled where studies were considered to be
clinically and statistically homogeneous, and pooled ef-
fect sizes (RR, OR, MD) and 95% CIs were calculated
using both fixed-effect and random-effects models using
inverse variance or Mantel-Haenszel methods. If there
was a connected network of three or more studies, then
indirect treatment comparisons and mixed treatment
comparisons (MTC) were performed. The underlying
assumptions of homogeneity, similarity and consistency in
the network were evaluated, as reported in Song et al.
[25]. All indirect comparisons and MTC methods followed
the guidance of the International Society for Pharma-
coeconomic and Outcomes Research (ISPOR) taskforce
recommendations for the conduct of indirect and MTC
meta-analysis [26]. Indirect comparisons were performed
according to the method developed by Bucher et al. [27].
Where feasible, an indirect estimate of the effect size was
calculated from the results of the corresponding direct
meta-analyses. If at least one ‘head-to-head’ study was
found, then an MTC (using a network of both ‘head-to-
head’ and indirect comparisons) was performed using
Bayesian methods. MDs, RRs and ORs (with 95% credible
interval [CrI]) were calculated for each outcome and
available treatment comparison using both fixed- and
random-effects models. Model fit was assessed and com-
pared between fixed- and random-effects models using the
deviance information criterion (DIC) [28]. MTC analyses
were performed using WinBUGS version 1.4.3 and the dir-
ect meta-analyses were performed using Cochrane Review
Manager Version 5.2 (RevMan 5.2). Sensitivity analysis
was used to investigate any studies which might not fulfill
the assumptions of similarity or homogeneity.
Results
Feasibility assessments
A flow chart illustrating the results of the search strategy
is shown in Figure 1. The systematic review identified 75
studies that satisfied the PICOS criteria. These studies
are summarized in Additional file 1: Appendix 3. Of
these, 11 studies could be included since they provided
data that could inform the indirect analyses of interest
(Figure 2) [13,15,16,29-36]. The RISE/RIDE [37] studies
did not inform the indirect analyses because they do not
comparative assessment with fluocinolone acetate, so
this indirect comparison was also not possible. Data for
two studies were based on an abstract and unpublished
clinical study reports at the time of review; however,
these studies are now published in full [13].
Two analyses were performed. Firstly, IVT-AFL 2q8
versus IVR 0.5 mg PRN using indirect analyses (Bucher
and MTC) based on the defined efficacy outcomes
(mean change from baseline in BCVA based on Early
Treatment Diabetic Retinopathy Study [ETDRS] score;
gain of ≥10 or ≥15 letters; and loss of ≥10 or ≥15 let-
ters) and safety outcomes (all adverse events [AEs]; all
serious AEs; all ocular AEs; all serious ocular AEs; all
non-ocular AEs; all serious non-ocular AEs; eye pain;
cataract; hypertension and all causes of mortality). Mean
change in BCVA was also adjusted for baseline visual
acuity score by including a treatment interaction effect
common across interventions in the MTC model [38].
Secondly, IVT-AFL 2q8 versus dexamethasone 0.7 mg
implants using an indirect analysis (Bucher) with defined
efficacy (gain ≥10 letters) and safety (macular edema,
reduced visual acuity, vitreous hemorrhage, eye pain,
increased intraocular pressure, and cataract) outcomes.
Efficacy outcomes: IVT-AFL 2q8 versus IVR 0.5 mg PRN
The assessment of clinical similarity showed that all
studies were randomized, and the majority had similar
designs (i.e., multicenter, double-blinded). With respect
to the inclusion/exclusion criteria, patients with macular
edema were classified by a range of anatomical and func-
tional measures. The main inclusion criteria included
significant DME [29], DME [30,31], focal or diffuse
DME [15,16,36], DME secondary to diabetes involving
the center of the macula [13], retinal thickening due to
DME [32-34] or clinically significant macula edema in
patients with diabetic retinopathy [35]. The visual acuity
at baseline is summarized in Table 2; studies reported
that visual acuity had to be 20/40 or worse [13,29] or
20/32 or worse [15,16], or patients had to have a BCVA
letter score of 34–70 [36], 39–78 at 4 meters [15,16],
24–73/78 [13,32,33] or 55–79 at 1 meter [34]. It was
difficult to compare baseline characteristics, due to lack
of consistency in reporting these items and absence of
these data, particularly in studies published only in
abstract form. Three studies were most dissimilar in this
regard [29,34,35].
Treatment interventions are listed in Table 2, and
treatment regimens are described in detail in Additional
file 1: Appendix 4. Most studies employed a laser control
arm (as described in Table 2). The need for additional
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Figure 1 Flow chart of the literature search.
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coherence tomography (OCT) or vision stability in most
studies and retreatment with laser was usually guided by
ETDRS guidelines. The studies varied regarding the risk
of bias. Six studies [13,15,29,33,35] all had a high risk
of bias for at least one domain, but four studies
[16,30-32,34] did not have high risk of bias in any do-
main (Additional file 1: Appendix 5). Based on clinical
assessments, the 10 studies included (particularly the
four studies included in the Bucher analysis) were con-
sidered sufficiently similar for fixed-effect analysis.
Direct and indirect analyses
IVT-AFL 2q8 and IVR 0.5 mg PRN could be directly
compared via a common comparator of laser (plus sham
injection) in four studies (Figure 3) [13,15,16]. These
comparisons showed that treatment with IVT-AFL 2q8
resulted in a significantly greater improvement in BCVA
mean change from baseline compared with laser (MD =
10.01 [95% CI: 8.32–11.69]). IVR 0.5 mg PRN also
showed a significant improvement compared with laser
(MD = 5.19 [95% CI: 3.63–6.75]). Only two studies were
The results from the indirect and MTC analyses
showed that IVT-AFL 2q8 improved the mean BCVA
change from baseline to a greater extent than IVR
0.5 mg PRN. The MD estimates from the fixed-effect
models were 4.67 [95% CrI: 2.45–6.87] (MTC; 10 stud-
ies) (Table 3A) and 4.82 [95% CI: 2.52–7.11] (Bucher;
four studies) (Table 3B). This effect remained after ad-
justment for baseline visual acuity score (the MD esti-
mate from the MTC fixed-effect model was 4.12 [95%
Crl: 1.47–6.81]) (Additional file 1: Appendix 7). IVT-
AFL 2q8 significantly reduced the loss of ≥ 10 ETDRS
letters at 12 months using MTC (RR = 0.27 [95% CrI:
0.07–0.90]) (six studies) but not Bucher analysis (RR =
0.31 [95% CI: 0.09–1.04]) (four studies) (Table 3). This
effect remained after adjustment for baseline visual acu-
ity score using MTC (RR = 0.11 [95% CrI: 0.02–0.46])
(Additional file 1: Appendix 7). There was no significant
difference between IVT-AFL 2q8 and IVR 0.5 mg PRN
treatments for gain of ≥10 ETDRS letters, gain of ≥15
ETDRS letters or loss of ≥15 ETDRS letters in either
MTC or Bucher analyses, with or without adjustment
l
l ll
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Figure 2 Final feasibility network at 12 months, showing direct comparisons by drug, comparator and dose. IVB, intravitreal bevacizumab; IVR,
intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; IVTA, intravitreal triamcinolone acetonide.
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Table 2 An overview of the studies (n = 11) included in the final analyses
Reference Phase Design Randomized
patients (n)
Inclusion Interventions Baseline
ETDRS score,
mean (SD)
Follow-up (months) Primary outcome Mean change in
BCVA (letters) at
Month 12
VIVID-DME [13] III Randomized,
double-blind,
multicenter
136
135
135
Patients with DME
secondary to diabetes
mellitus. BCVA ETDRS
letter score between 24
and 73 in the study eye
IVT-AFL 2q4*
IVT-AFL 2q8*
Laser*
60.8 (10.7)
58.8 (11.2)
60.8 (10.6)
12 Mean change in BCVA
(ETDRS letters score) at
Week 52
+10.5
+10.7
+1.2
VISTA-DME [13] III Randomized,
double-blind,
multicenter
156
154
156
Patients with DME
secondary to diabetes
mellitus. BCVA ETDRS
letter score between 24
and 73 in the study eye
IIVT-AFL 2q4*
IVT-AFL 2q8*
Laser*
58.9 (10.8)
59.4 (10.9)
59.7 (11.0)
12 Mean change in BCVA
(ETDRS letters score) at
Week 52
+12.5
+10.7
+0.2
IBETA [29] Abstract III Randomized,
open,
single center
23
21
20
Clinically significant DME.
Snellen logarithm of
minimum angle of
20/40 or worse
Laser fixed → PRN
IVB 1.5 mg + laser
IVTA 4 mg + laser
NR
NR
NR
12 Outcomes included
BCVA, OCT-CMT at
Week 52
+9.5
+11.5
+12.5
RESTORE [15] III Randomized,
double-blind,
multicenter
111
116
118
Focal or diffuse DME.
BCVA letter score
between 39 and 78
Laser fixed q4 → PRN*
IVR 0.5 mg q4 → PRN*
IVR 0.5 mg + laser
62.4 (11.1)
64.8 (10.1)
63.4 (10.0)
12 Mean average change in
BCVA from baseline to
Month 1 through 12
+0.8
+6.1
+5.9
REVEAL [16]
Abstract
III Randomized,
double-blind,
multicenter
133
132
131
Focal or diffuse DME.
BCVA letter score
between 39 and 78
IVR 0.5 mg q4 → PRN*
IVR 0.5 mg + laser
Laser fixed q4 → PRN*
NR
NR
NR
12 Mean average change
in BCVA from baseline to
Month 1 through 12
+6.6
+6.4
+1.8
RELATION [30,31]
Abstracts
III Randomized,
double-blind,
multicenter
85
43
DME IVR 0.5 mg + prompt laser
Laser fixed q4 → PRN*
NR
NR
12 Changes in BCVA,
OCT-CRT, and FA
+6.5
+1.4
DRCR.net
Protocol I [32]
III Randomized,
double-blind,
multicenter
293
187
188
186
DME. BCVA letter score
between 24 and 78
Laser fixed q4 → PRN*
IVR 0.5 mg + prompt laser
IVR 0.5 mg + deferred laser
IVTA 4 mg + laser
NR
NR
NR
NR
12 (maximum 36) Mean change in BCVA at
month 12
+3
+9
+9
+4
DRCR.net
Protocol J [33]
III Randomized,
double-blind,
multicenter
123
113
109
DME and presence of
severe NPDR or PDR.
ETDRS letter score ≥ 24
Laser fixed*
IVR 0.5 mg + laser
IVTA 4 mg + laser
NR
NR
NR
12 Mean change in visual
acuity from baseline to
Week 14
−6
−4
−5
LUCIDATE [34]
Abstract
IV Randomized,
open,
single center
11
11
DME.
BCVA letter score
between 55 and 79
IVR 0.5 mg q4 → PRN
Laser fixed → PRN
NR
NR
11 BCVA ETDRS VA, FA, OCT,
microperimetry, full-field
and multifocal ERG at
Week 48
+6.0
−0.9
Maia et al.
(2009) [35]
II/III Randomized,
single-blind,
single center
22
22
DR and CSME.
ETDRS severity level 65
Laser fixed → PRN
IVTA 4 mg + laser
NR
NR
12 Changes in BCVA, CMT,
and TMV
+3**
+16**
PLACID [36] II Randomized,
double-blind,
multicenter
126
127
Diffuse DME.
BCVA letter score
between ≥ 34 and≤ 70
Dexamethasone fixed → PRN
Laser fixed → PRN*
57 (9.4)
57.5 (9.5)
12 Proportion who gained
≥ 10 letters from
baseline to Month 12
NA
BCVA, best-corrected visual acuity; CMT, central macular thickness; CRT, central retinal thickness; CSME, clinically significant macular edema; DME, diabetic macular edema; DR, diabetic retinopathy; ERG, electroretinography;
ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluorescein angiography; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; IVTA, intravitreal triamcinolone acetonide; NA, not
available; NPDR, non-proliferative diabetic retinopathy; NR, not reported; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRN, as needed; TMV, total macular volume; VA, visual acuity.
*Includes sham. **Published as logarithm of the minimum angle of resolution used, converted here to ETDRS letters using Gregori NZ, et al. Retina. 2010; 30:1046-50.
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raising a question about the effects of an Asian subpop-
ulation effect on the main analysis. When this study
(Ohji et al. [16]) was excluded, the overall effect
remained similar; the difference in mean BCVA change
from baseline was 4.11 [95% CI: 0.99–7.22] by Bucher
analysis.
Efficacy outcomes: IVT-AFL 2q8 versus dexamethasone
0.7 mg implants
Two studies [13] reported data to allow a direct analysis
between IVT-AFL 2q8 (plus sham laser) versus laser
(plus sham injection) for the outcome ‘gain of ≥10
ETDRS letters’, with an RR = 2.50 [95% CI: 1.97–3.17].
Table 3 Indirect comparisons of the effects of IVT-AFL 2q8 versus IVR 0.5 mg PRN on 12-month visual outcomes using
(A) MTC and (B) Bucher analyses
(A)
MTC Studies (n) FE: effect size [95% CrI] RE: effect size [95% CrI]
BCVA mean change from baseline 10 studies (n = 3060)* MD = 4.67 [2.45–6.87] MD = 4.67 [1.85–7.52]
Gain ≥ 10 ETDRS letters 6 studies (n = 2810)** RR = 1.32 [0.98–1.78] RR = 1.19 [0.90–1.57]
OR = 1.64 [0.97–2.78] OR = 1.59 [0.75–3.35]
Loss ≥ 10 ETDRS letters 6 studies (n = 2810)** RR = 0.27 [0.07–0.90] RR = 0.28 [0.06–1.29]
OR = 0.27 [0.07–0.90] OR = 0.26 [0.05–1.31]
Gain ≥ 15 ETDRS letters 6 studies (n = 2810)** RR = 1.78 [0.96–3.29] RR = 1.42 [0.93–2.24]
OR = 1.90 [0.95–3.75] OR = 1.87 [0.87–4.16]
Loss ≥ 15 ETDRS letters 6 studies (n = 2810)** RR = 0.13 [0.004–1.35] RR = 0.14 [0.007–1.52]
OR = 0.13 [0.004–1.35] OR = 0.14 [0.006–1.53]
(B)
Bucher Studies (n) FE: effect size [95% CI] RE: effect size [95% CI]
BCVA mean change from baseline 4 studies (n = 1611)*** MD = 4.82 [2.52–7.11] MD = 4.82 [2.52–7.11]
Gain ≥ 10 ETDRS letters 4 studies (n = 1611)*** RR = 0.993 [0.65–1.52] RR = 1.00 [0.60–1.66]
OR = 1.32 [0.74–2.35] OR = 1.32 [0.65–2.68]
Loss ≥ 10 ETDRS letters 4 studies (n = 1611)*** RR = 0.31 [0.09–1.04] RR = 0.31 [0.09–1.09]
OR = 0.28 [0.08–0.99] OR = 0.27 [0.08–0.94]
Gain ≥ 15 ETDRS letters 4 studies (n = 1611)*** RR = 1.49 [0.78–2.85] RR = 1.49 [0.78–2.85]
OR = 1.74 [0.83–3.65] OR = 1.74 [0.83–3.65]
Loss ≥ 15 ETDRS letters 4 studies (n = 1611)*** RR = 0.24 [0.03–1.90] RR = 0.26 [0.03–2.11]
OR = 0.23 [0.03–1.86] OR = 0.23 [0.03–1.86]
l
l
l
ll
l
l
l
l
l
l l
Figure 3 Direct comparison of IVT-AFL 2q8 (plus sham laser) or IVR 0.5 mg PRN (plus sham laser) versus laser (plus sham injection) for mean BCVA
change from baseline in key studies. Indirect comparison (IVT-AFL 2q8 vs IVR 0.5 mg PRN) (Bucher analysis) also shown. BCVA, best-corrected visual
acuity; CI, confidence interval; IVR, intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; PRN, as-needed; VEGF, vascular endothelial growth factor.
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This analysis showed moderate heterogeneity (I2 = 56%).
Only one study [36] reported a gain of ≥10 ETDRS letters
for the comparison of dexamethasone 0.7 mg (plus laser)
versus laser (plus sham implant); therefore, no direct
meta-analysis was possible. This study reported an RR =
1.18 [95% CI: 0.77–1.79]. Indirect analyses of these three
studies showed that IVT-AFL 2q8 improved the propor-
tion of patients gaining≥10 ETDRS letters at 12 months
compared with dexamethasone 0.7 mg implants (RR =
2.10 [95% CI: 1.29–3.40], fixed-effect model) (Table 4).
Analyses of other efficacy outcomes were not feasible.
Safety outcomes
There was moderate heterogeneity for comparisons be-
tween IVT-AFL 2q8 and laser (based on two studies)
for all serious AEs (I2 = 55%), all AEs (I2 = 55%), all-
serious non-ocular AEs (I2 = 52%) and all-causes of
mortality (I2 = 47%); there was high heterogeneity for all
non-ocular AEs (I2 = 86%). There was moderate hetero-
geneity for comparisons between IVR 0.5 mg PRN and
laser for all serious ocular AEs (I2 = 67%; two studies)
(Additional file 1: Appendix 8). None of these direct
comparisons achieved statistical significance. The
analyses were limited by differences in the precise
definition for the safety outcomes. These definitions are
listed in Additional file 1: Appendix 9. There were no
significant differences in safety outcomes between IVT-
AFL 2q8 and IVR 0.5 mg PRN in either the MTC
(Table 5) or Bucher analyses (data not reported). How-
ever, there were few events reported in the studies,
which resulted in wide CI intervals (summarized in
Additional file 1: Appendix 8).
Direct analyses showed that there was moderate het-
erogeneity between IVT-AFL 2q8 and laser for increased
intraocular pressure (I2 = 73%) and vitreous hemorrhage
(I2 = 60%), and low heterogeneity for cataract (I2 = 38%)
(Additional file 1: Appendix 10). None of these direct
comparisons achieved statistical significance. Indirect
analyses showed that there were no significant differ-
ences between IVT-AFL 2q8 and dexamethasone 0.7 mg
implants for the outcomes: macular edema, reduced vis-
ual acuity, vitreous hemorrhage, eye pain, increased in-
traocular pressure and cataracts; however, there was a
trend toward fewer events with IVT-AFL 2q8 compared
with dexamethasone 0.7 mg implants (Table 6).
Discussion
The aim of this systematic review was to identify and
review studies informing the clinical effectiveness of
IVT-AFL 2q8 in relation to other DME treatments, and
to prepare where possible indirect comparisons of IVT-
AFL 2q8 against other regimens licensed outside the
USA at the time the analyses were conducted (i.e., IVR
0.5 mg PRN, dexamethasone 0.7 mg implants or fluoci-
nolone acetate 0.2 μg/day implants). The evidence from
these specific comparisons showed a benefit of IVT-
AFL 2q8 over IVR 0.5 mg PRN for the improvement of
mean change from baseline in BCVA (+4.67 letters
before adjustment for baseline visual acuity and +4.12
after adjustment), the primary efficacy endpoint of
VIVID-DME/VISTA-DME [13], and that approximately
70% fewer patients showed a loss of ≥ 10 ETDRS letters,
an exploratory endpoint. These results were consistent
in multiple analyses, including both MTC analyses
(which included up to 10 studies and 3060 patients
with DME) and in Bucher analyses (four studies of
1611 patients with DME), and remained consistent
when one study in Asian patients [16] was included or
excluded from the Bucher analysis. There were no sig-
nificant differences between IVT-AL 2q8 and IVR
0.5 mg PRN in safety outcomes (for each of the safety
outcomes where quantitative analysis was possible).
However, the analysis was limited by differences in defi-
nitions of AEs between studies, and the total number of
AEs in studies was low resulting in wide CIs.
The evidence also favored IVT-AFL 2q8 over dexa-
methasone in an indirect analysis of three studies with
up to 1123 DME patients. More patients (approximately
twice as many) receiving IVT-AFL 2q8 showed a gain
of ≥10 ETDRS letters compared with those receiving
dexamethasone. There were also fewer patients treated
with IVT-AFL 2q8 who experienced increased intraoc-
ular pressure compared with dexamethasone 0.7 mg
implants. There were an additional five safety out-
comes (macular edema, reduced visual acuity, vitreous
hemorrhage, eye pain and cataract) that showed a non-
significant trend in favor of IVT-AFL 2q8. Dexametha-
sone was recently approved for the treatment of adults
with visual impairment due to DME who are pseudo-
phakic or insufficiently responsive/unsuitable for non-
corticosteroid therapy. This is more restrictive than
Table 4 Indirect comparison (Bucher analysis) of the effects of IVT-AFL 2q8 versus dexamethasone 0.7 mg implants on
12-month visual outcomes
Outcome Studies (n) FE: effect size [95% CI] RE: effect size [95% CI]
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Table 5 Indirect comparison (MTC analysis) of IVT-AFL 2q8 versus IVR 0.5 mg PRN for 12-month safety outcomes
Outcome Studies (n) FE: effect size [95% CrI] RE: effect size [95% CrI]
All AEs 5 studies (n = 1739)* RR = 0.79 [0.55–1.10] RR = 0.88 [0.64–1.15]
OR = 0.61 [0.29–1.26] OR = 0.58 [0.18–1.82]
All serious AEs 5 studies (n = 1739)* RR = 0.76 [0.47–1.26] RR = 0.82 [0.47–1.42]
OR = 0.71 [0.39–1.32] OR = 0.74 [0.31–1.72]
All serious ocular AEs 5 studies (n = 1739)* RR = 0.28 [0.06–1.24] RR = 0.30 [0.05–2.49]
OR = 0.27 [0.05–1.25] OR = 0.28 [0.05–2.58]
All serious non-ocular AEs 4 studies (n = 1343)** RR = 0.60 [0.32–1.14] RR = 0.67 [0.29–1.66]
OR = 0.53 [0.24–1.17] OR = 0.53 [0.12–2.11]
All ocular AEs 4 studies (n = 1343)** RR = 0.75 [0.54–1.05] RR = 0.85 [0.58–1.25]
OR = 0.60 [0.32–1.09] OR = 0.58 [0.16–1.87]
All non-ocular AEs 3 studies (n = 1215)*** RR = 1.09 [0.87–1.40] RR = 1.03 [0.80–1.56]
OR = 1.27 [0.65–2.42] OR = 1.22 [0.23–6.18]
Eye pain 4 studies (n = 1343)** RR = 0.98 [0.38–2.70] RR = 0.96 [0.23–3.91]
OR = 0.97 [0.34–2.94] OR = 0.95 [0.17–4.75]
Cataract 3 studies (n = 1215)*** RR = 3.93 [0.77–32.74] RR = 3.83 [0.52–43.72]
OR = 4.09 [0.76–34.86] OR = 4.16 [0.49–50.98]
Hypertension 4 studies (n = 1343)** RR = 0.95 [0.44–2.07] RR = 0.95 [0.37–2.55]
OR = 0.95 [0.40–2.22] OR = 0.94 [0.28–3.14]
All causes of mortality 3 studies (n = 1215)*** RR = 2.90 [0.20–50.4] RR = 2.76 [0.13–79.02]
OR = 3.06 [0.18–60.01] OR = 2.83 [0.11–85.27]
*VIVID-DME, VISTA-DME, RESTORE, REVEAL, and RELATION [13,15,16,30,31].
**VIVID-DME, VISTA-DME, RESTORE, and RELATION [13,15,30,31].
***VIVID-DME, VISTA-DME, and RESTORE [13,15].
AE, adverse event; CrI, credible interval; FE, fixed effects; IVR, intravitreal ranibizumab; IVT-AFL, intravitreal aflibercept; MTC, mixed treatment comparison; OR, odds
ratio; PRN, as needed; RE, random effects; RR, relative risk/risk ratio.
Table 6 Indirect comparison (Bucher analysis) of IVT-AFL 2q8 versus dexamethasone 0.7 mg implants for 12-month
safety outcomes
Outcome Studies (n) FE: effect size [95% CI] RE: effect size [95% CI]
Macular edema 2 studies (n = 657)* RR = 0.22 [0.03–1.67] RR = 0.22 [0.03–1.64]
OR = 0.21 [0.03–1.69] OR = 0.21 [0.03–1.70]
Reduced visual acuity 3 studies (n = 1123)** RR = 0.64 [0.24–1.67] RR = 0.64 [0.17–2.40]
OR = 0.61 [0.21–1.77] OR = 0.61 [0.21–1.77]
Vitreous hemorrhage 3 studies (n = 1123)** RR = 0.30 [0.07–1.39] RR = 0.18 [0.02–1.65]
OR = 0.28 [0.06–1.38] OR =0.16 [0.02–1.54]
Eye pain 3 studies (n = 1123)** RR = 0.80 [0.29–2.21] RR = 0.78 [0.27–2.21]
OR = 0.79 [0.26–2.38] OR = 0.76 [0.24–2.38]
Increased intraocular pressure 3 studies (n = 1123)** RR = 0.08 [0.02–0.42] RR = 0.13 [0.01–1.79]
OR = 0.07 [0.01–0.37] OR = 0.11 [0.01–1.54]
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the population included in this review, and no data
were identified to analyze this subgroup separately.
To date, four key systematic reviews for DME have in-
cluded IVT-AFL 2q8 [17-19,39]. Based on an indirect
analysis of 15 randomized studies and eight observa-
tional studies of anti-VEGF therapies (IVT-AFL, intra-
vitreal bevacizumab [IVB], IVR and pegaptanib) by
Ollendorf et al. [17], it was concluded that anti-VEGF
therapy is associated with sustained visual improvements
and reduced rescue laser, but there was insufficient evi-
dence to distinguish between treatments [17]. However,
this comparison was based on a less rigorous analysis
(pairwise indirect comparisons) – without testing for
bias or heterogeneity. The review by Ford et al. [40] in-
cluded the DA VINCI study as the only source of data
for IVT-AFL; as mentioned, DA VINCI has a different
loading dose regimen to VIVID-DME and VISTA-DME,
and there are only 221 patients in this study, divided
over five treatment groups, compared with 406 in
VIVID-DME and 466 in VISTA-DME [11,13]. Although
the Cochrane review by Virgili et al. [18] included
VIVID-DME and VISTA-DME, it focused on endpoints
measured in logMAR rather than the more usual change
in BCVA from baseline, which is included in this review.
In addition, our analysis did not pool data using differ-
ent IVR dosing regimens (such as PRN or quarterly) and
did not include data from heterogeneous IVR studies or
time points, which has also been undertaken in earlier
meta-analyses. The most recent review by Regnier et al.
[39] included Bayesian network meta-analyses based on
eight randomized controlled studies that evaluated IVR
0.5 mg PRN, IVT-AFL 2q8, laser photocoagulation or
sham in 1978 patients, and reported 6- and 12-month
outcomes. The IVT-AFL data included were from three
studies (DA VINCI, VIVID-DME, and VISTA-DME)
[11,13]. This review concluded that both IVR 0.5 mg
PRN and IVT-AFL 2q8 were statistically superior to
laser monotherapy (OR = 5.50 and OR = 3.45, respect-
ively) and that the treatment effect of IVR was numeric-
ally, but not statistically, superior to IVT-AFL (OR =
1.59 [95% CrI 0.61–5.37]). However, the analyses relate
to one secondary efficacy outcome (relative risk of ≥10
letter gain at 12 months), not the primary efficacy out-
come in any pivotal phase III study of IVR or IVT-AFL
(mean gain in BCVA at 12 months in VIVID-DME/
VISTA-DME), and there was a lack of detail on the ra-
tionale for data inclusion and extraction, assessment of
bias and statistical methods used for adjustment. The
current review includes a broader range of interventions
(including dexamethasone), and more than one outcome
not statistically significant, but that the direction of effect
favors IVT-AFL 2q8 (OR= 1.64 [95% CrI 0.97–2.78]). The
difference in direction of point estimates between the
studies appears largely attributable to the selection of
studies and data rather than, for instance, choice of treat-
ment effect measure (OR rather than RR) or any statistical
adjustments applied by Regnier et al. [39].
Since we conducted the review and analysis presented
here, the Diabetic Retinopathy Clinical Research Net-
work (DRCRnet) has published first year results of the
Protocol T study, which directly compared the 12-month
outcomes of patients with DME randomized to either
IVT-AFL (n = 224), IVR (n = 218) or IVB (n = 218) [20].
Study drugs were administered monthly according to a
predefined protocol. The mean difference in BCVA (pri-
mary endpoint) at 12 months for IVT-AFL 2 mg versus
ranibizumab 0.3 mg was +2.1 letters (P= 0.03) overall,
and +4.7 letters (P= 0.003) in patients with baseline
letter score < 69 letters. Prespecified ocular AEs and
serious AEs, and Antiplatelet Trialists’ Collaboration-
defined arterial thromboembolic events were not signifi-
cantly different between the three anti-VEGF agents.
These findings are comparable with those observed in
this analysis where the difference between IVT-AFL and
IVR was +4.67 letters (MTC analysis). In the Protocol T
study, baseline visual acuity was predictive of outcome
[20]. In the current analysis, the difference between
IVT-AFL and IVR remained (+4.12 letters; MTC ana-
lysis) after adjustment for aggregate differences between
studies and treatment arms in baseline visual acuity.
While this may be an improvement on making no ad-
justment, incorporating head-to-head studies or individ-
ual patient data could provide further strength to the
analysis. It must also be noted that Protocol T included
IVR 0.3 mg dose and would, therefore, have been ex-
cluded from the current analysis of licensed doses (only
IVR 0.5 mg would have been included).
The current review has a number of strengths that are
inherent with a meta-analysis (including the use of com-
bined data to increase the statistical power to detect an
effect). Systematic reviews of high-quality evidence are
also regarded at the higher end of the hierarchy of
evidence [41]. This review adhered to international recom-
mendations and guidelines in order to reduce bias in pub-
lication selection, including pre-specification of inclusion/
exclusion criteria and pre-specification of indirect compar-
isons of interest. Extensive consideration was also given to
clinical and statistical heterogeneity, and appropriate
stratification of studies by intervention and posology was
applied. Based on this, the network of 10 studies inform-
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However, despite efforts to minimize bias and hetero-
geneity, these analyses do have a number of limitations,
which are inherent in modeling approaches that use
indirect data comparisons. Many studies had unclear or
high risk of bias in at least one domain of the Cochrane
risk of bias tool, and type 1/type 2 errors that already
exist in published studies may also bias any meta-
analysis extrapolating that hypothesis. The most com-
mon issue was inadequate masking (data not shown).
Patient baseline characteristics differed, such as in the
mean or range of BCVA of patients (Table 2), or were
often poorly reported, which made it difficult to com-
pare populations between studies. The findings are also
based on a small number of studies and should be inter-
preted with caution. Tests of statistical significance are
reported without adjustment for multiplicity of out-
comes. This paper also included 12-month data only,
which was based on availability at the time of the review.
Some studies now have longer-term outcomes available.
While the scope of the analysis (limited to licensed
agents) ensures that the studies and datasets included
are not excessively heterogeneous, there are important
studies such as Protocol T and RISE/RIDE outside this
scope which would be relevant in any broader assess-
ment of comparative effectiveness of anti-VEGF agents.
It must be noted that the paper reports on selected
safety outcomes, which were associated with the feasible
networks, and did not compare systemic safety among
different doses of DME therapies in detail. A meta-
analysis of 11 studies (6596 patients) that compared sys-
temic safety in relation to different regimens (doses and
frequencies) of ranibizumab treatment (but for age-related
macular degeneration [AMD]) identified a possible rela-
tionship associated with monthly versus as-needed dosing
for cerebrovascular accidents [42]. Another meta-analysis
of 21 studies (9557 patients) that compared systemic safety
of anti-VEGF treatment in AMD, DME and retinal vein
occlusion found no association between anti-VEGF and
increased mortality or vascular events [43]. In our analysis,
the selection of feasible networks only may have resulted
in under-powering, and the introduction of type 2 errors;
however, a complete comparison of systemic safety was
out of scope.
Conclusions
This indirect comparison suggests that IVT-AFL 2q8
after a loading dose of 5 monthly injections improved
visual acuity outcomes (‘BCVA mean change from base-
line’ and ‘loss ≥10 ETDRS letters’) in eyes with center-
involved DME to a greater extent than IVR 0.5 mg PRN,
a number of strengths, including the adherence to
international guidelines for performing indirect ana-
lyses, inclusion of prespecified inclusion and exclusion
criteria, and comprehensive assessment of clinical and
statistical heterogeneity, it does have a number of limi-
tations inherent with indirect analyses, the scope is nar-
row, and the conclusions must be interpreted with
caution. Many studies had unclear or high risk of bias
in at least one domain of the Cochrane risk of bias tool,
and safety outcomes were limited by differences in
definitions of events. The number of events reported
across studies was low, and the CIs were wide. There is
a need for more studies comparing the relative effects
of licensed therapies for DME in order to select the
best treatment options for our patients; however, the
findings from this indirect analysis are comparable to
those published in the Protocol T study, which directly
compared IVT-AFL with other anti-VEGF agents in
patients with DME.
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